The handshake agreement over 10 years ago was simple.

Market Scope would attend the Glaucoma Research Foundation’s annual three-day Glaucoma 360 meeting, consisting of a fundraising gala, the New Horizons Forum innovation event, and CME/CE symposia.

The company also would execute an online survey of attendees on important issues and new technologies discussed at the meeting, plus make a donation to the GRF on behalf of each participant.

Market Scope would share the survey results with GRF leadership for use at the meeting and to provide to industry and clinical attendees.

Collectively, Market Scope has raised over $29 thousand for the GRF since our inaugural survey.

As of Feb. 12, 50 ophthalmologists (MDs) and 102 optometrists (ODs) completed the 2025 Annual G360 Survey. A sneak peek of results shows that more than 69 percent of ODs found insurance coverage important when selecting glaucoma medication.

When MDs were asked which emerging glaucoma laser technology would be most impactful, nearly 59 percent selected direct selective laser trabeculoplasty (DSLT).

More News

Want to Read Locked Articles?

Already Have an Account?

Register A Corporate Account

Topics of Interest

Products of Interest